Section of Cardiology, San Francisco Veterans Affairs Medical Center, 111C, 4150 Clement Street, San Francisco, CA, 94121-1545, USA.
Pflugers Arch. 2014 Jun;466(6):1219-25. doi: 10.1007/s00424-014-1528-9. Epub 2014 May 6.
Heart failure therapy has seen many advances over the last 40 years and has rapidly expanded beyond diuretics and digoxin to include several new mechanisms of action and devices whose efficacy had been demonstrated in large clinical trials. The evidence for their use is thoroughly summarized and discussed in current heart failure treatment guidelines and is not the subject of this review. Despite these advances, the mortality and morbidity in heart failure patients is still substantial, and there remains a need to develop new heart failure therapies. Recognizing that advances in medical therapy are often driven by the introduction of drugs with novel mechanisms of action, here we provide an overview of investigative heart failure drugs with novel mechanisms of action that are the subject of ongoing clinical trials.
在过去的 40 年里,心力衰竭治疗取得了许多进展,迅速超越了利尿剂和地高辛,涵盖了几种新的作用机制和设备,这些机制和设备的疗效已在大型临床试验中得到证实。目前心力衰竭治疗指南中对这些药物的使用进行了全面总结和讨论,不在本次综述的范围内。尽管取得了这些进展,但心力衰竭患者的死亡率和发病率仍然很高,仍然需要开发新的心力衰竭治疗方法。鉴于医学治疗的进展通常是由具有新作用机制的药物的引入所驱动的,因此在这里我们对正在进行临床试验的具有新作用机制的研究性心力衰竭药物进行概述。